Guaiphenesin

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.